Literature DB >> 12700915

Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy.

I M Bronner1, J E Hoogendijk, A R Wintzen, M F G van der Meulen, W H J P Linssen, J H J Wokke, M de Visser.   

Abstract

OBJECTIVE: To evaluate the clinical features, muscle pathology and response to treatment in patients with a necrotising myopathy, without mononuclear cell infiltrates.
BACKGROUND: Mononuclear cell infiltrates in the muscle biopsy specimen are the diagnostic hallmark of the immune-mediated idiopathic inflammatory myopathies (IIM). In patients with the typical clinical features of IIM, absence of these infiltrates in the muscle biopsy specimen casts doubt on the diagnosis and leads to uncertainty about therapeutical strategies.
METHODS: A detailed description is given of the clinical, laboratory, and histopathological features of eight patients suspected of having an idiopathic inflammatory myopathy, in whom mononuclear cell infiltrates in their muscle biopsy specimens were lacking.
RESULTS: Eight patients (five men, three women, age range 40-69 years) had severe, symmetrical proximal weakness with a subacute onset. There were no skin abnormalities suggesting dermatomyositis. Serum creatine kinase activity was more than 10 times elevated. Repeated muscle biopsy specimens, taken from a symptomatic muscle prior to immunosuppressive treatment showed widespread necrosis, regeneration, and atrophy of muscle fibres, but no mononuclear cell infiltrates. Known causes of necrotising myopathy were excluded. Three patients had a malignancy. Adequately dosed and sustained immunosuppressive treatment eventually resulted in normal or near normal muscle strength in seven patients. One patient showed marked improvement.
CONCLUSION: Occasionally, patients who clinically present as an idiopathic inflammatory myopathy may lack mononuclear cell infiltrates in their muscle biopsy specimens. This subacute-onset progressive necrotising myopathy should not deter the clinician from timely and appropriate treatment as we consider this myopathy to be steroid-responsive with a possible immune-mediated pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12700915     DOI: 10.1007/s00415-003-1027-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  19 in total

1.  Long-term follow-up of 62 patients with myositis.

Authors:  Janneke van de Vlekkert; Jessica E Hoogendijk; Marianne de Visser
Journal:  J Neurol       Date:  2014-05       Impact factor: 4.849

2.  Inflammatory myopathies.

Authors:  B Jane Distad; Anthony A Amato; Michael D Weiss
Journal:  Curr Treat Options Neurol       Date:  2011-04       Impact factor: 3.598

Review 3.  Immune-Mediated Necrotizing Myopathy: Update on Diagnosis and Management.

Authors:  Pari Basharat; Lisa Christopher-Stine
Journal:  Curr Rheumatol Rep       Date:  2015-12       Impact factor: 4.592

4.  Intravenous human immunoglobulin and/or methylprednisolone pulse therapies as a possible treat-to-target strategy in immune-mediated necrotizing myopathies.

Authors:  Jean Marcos de Souza; Leonardo Santos Hoff; Samuel Katsuyuki Shinjo
Journal:  Rheumatol Int       Date:  2019-02-18       Impact factor: 2.631

Review 5.  Immune-mediated necrotizing myopathy.

Authors:  C Bergua; H Chiavelli; J P Simon; O Boyer; F Jouen; W Stenzel; J Martinet
Journal:  Z Rheumatol       Date:  2016-03       Impact factor: 1.372

6.  Long-term outcome in polymyositis and dermatomyositis.

Authors:  I M Bronner; M F G van der Meulen; M de Visser; S Kalmijn; W J van Venrooij; A E Voskuyl; H J Dinant; W H J P Linssen; J H J Wokke; J E Hoogendijk
Journal:  Ann Rheum Dis       Date:  2006-04-10       Impact factor: 19.103

Review 7.  Idiopathic inflammatory myopathies.

Authors:  Mazen M Dimachkie; Richard J Barohn; Anthony A Amato
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

Review 8.  Diagnosis, pathogenesis and treatment of myositis: recent advances.

Authors:  P-O Carstens; J Schmidt
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

9.  Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle.

Authors:  Iago Pinal-Fernandez; Cassie Parks; Jessie L Werner; Jemyma Albayda; Julie Paik; Sonye K Danoff; Livia Casciola-Rosen; Lisa Christopher-Stine; Andrew L Mammen
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-12-31       Impact factor: 4.794

10.  Paraneoplastic Necrotizing Myopathy with a Mild Inflammatory Component: A Case Report and Review of the Literature.

Authors:  Susanne Wegener; Juliane Bremer; Paul Komminoth; Hans H Jung; Michael Weller
Journal:  Case Rep Oncol       Date:  2010-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.